Table 2.
Pathological classification of all thyroid malignancies from 1994 to 2015
| Period | 94–95 | 96–97 | 98–99 | 00–01 | 02–03 | 04–05 | 06–07 | 08–09 | 10–11 | 12–13 | 14–15 | P for difference | P for trend |
| PTC, n (%) | 15 (65.3) | 17 (77.3) | 17 (73.9) | 39 (70.9) | 50 (70.4) | 107 (82.3) | 185 (86.4) | 383 (94.6) | 768 (94.0) | 1376 (97.4) | 2023 (98.2) | <0.001 | <0.001 |
| FTC, n (%) | 3 (13.0) | 1 (4.5) | 4 (17.3) | 10 (18.1) | 9 (12.7) | 17 (13.1) | 18 (8.4) | 9 (2.2) | 25 (3.0) | 17 (1.2) | 20 (0.9) | <0.001 | <0.001 |
| MTC, n (%) | 1 (4.3) | 2 (9.1) | 1 (4.3) | 4 (7.3) | 2 (2.8) | 1 (0.8) | 2 (0.9) | 5 (1.2) | 14 (1.7) | 12 (0.8) | 12 (0.6) | <0.001 | <0.001 |
| ATC, n (%) | 0 (0) | 0 (0) | 1 (4.3) | 1 (1.8) | 3 (4.2) | 1 (0.8) | 1 (0.5) | 2 (0.5) | 1 (0.1) | 1 (0.1) | 2 (0.1) | <0.001 | <0.001 |
| Other, n (%) | 4 (17.4) | 2 (9.1) | 0 (0) | 1 (1.8) | 7 (9.9) | 4 (3.1) | 7 (3.3) | 6 (1.5) | 9 (1.1) | 7 (0.5) | 3 (0.1) | <0.001 | <0.001 |
| Unilateral | 14 (60.9) | 14 (63.6) | 13 (56.5) | 31 (56.4) | 38 (53.5) | 72 (55.4) | 122 (57.0) | 213 (52.6) | 389 (47.6) | 616 (43.6) | 991 (48.1) | 0.071 | <0.001 |
| Bilateral | 9 (39.1) | 8 (36.4) | 10 (43.5) | 24 (43.6) | 33 (46.5) | 58 (44.6) | 92 (43.0) | 192 (47.4) | 428 (52.4) | 797 (56.4) | 1069 (51.9) | ||
| Solitary | 7 (30.4) | 13 (59.1) | 11 (47.8) | 27 (49.1) | 28 (39.4) | 59 (45.4) | 105 (49.0) | 172 (42.5) | 292 (35.7) | 456 (32.3) | 749 (36.4) | <0.001 | <0.001 |
| Multiple | 16 (69.6) | 9 (40.9) | 12 (52.2) | 28 (50.9) | 43 (60.6) | 71 (54.6) | 109 (51.0) | 233 (57.5) | 525 (64.3) | 957 (67.7) | 1311 (63.6) | ||
| All cancer, n | 23 | 22 | 23 | 55 | 71 | 130 | 214 | 405 | 817 | 1413 | 2060 |
ATC, anaplastic thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; other histotypes of carcinoma collectively refer to cancer other than PTC, FTC, MTC and ATC, including poorly differentiated thyroid cancer, squamous cell carcinomas, B cell lymphomas of thyroid, spindle cell carcinoma, adenoid cystic carcinoma, renal clear cell metastasis and Langerhans cell histocytosis of the thyroid gland; PTC, papillary thyroid carcinoma.